National Academies ofSciences, Engineering, andMedicine. The Health Effects of Cannabis and Cannabinoids: The Current State of Evidence and Recommendations for Research. The National Academies Press: Washington, DC, 2017.
2.
WhitingPF, WolffRF, DeshpandeS, et al.Cannabinoids for medical use: a systematic review and meta-analysis. JAMA. 2015; 313:2456–2473.
3.
NugentSM, MorascoBJ, O'NeilME, et al.The effects of cannabis among adults with chronic pain and an overview of general harms: a systematic review. Ann Intern Med. 2017; 167:319–331.
4.
StockingsE, CampbellG, HallWD, et al.Cannabis and cannabinoids for the treatment of people with chronic noncancer pain conditions: a systematic review and meta-analysis of controlled and observational studies. Pain. 2018; 159:1932–1954.
5.
Torres-MorenoMC, PapaseitE, TorrensM, et al.Assessment of efficacy and tolerability of medicinal cannabinoids in patients with multiple sclerosis: a systematic review and meta-analysis. JAMA Netw Open. 2018; 1:e183485.
6.
YadavV, BeverCJr, BoewnJ, et al.Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology. Neurology. 2014; 82:1083–1092.
7.
Mabou TagneA, PacchettiB, SodergrenM, et al.Cannabidiol for viral diseases: hype of hope?. Cannabis Cannabinoid Res. 2020; 5:121–131.
8.
D'EliaRV, HarrisonK, OystonPC, et al.Targeting the “Cytokine Storm” for therapeutic benefit. Clin Vaccine Immunol. 2013; 20:319–327.
9.
ReissCS. Cannabinoids and viral infections. Pharmaceuticals. 2010; 3:1873–1886.
10.
TahamtanA, Tavakoli-YarakiM, RygielTP, et al.Effects of cannabinoids and their receptors on viral infections. J Med Virol. 2016; 88:1–12.
11.
FeliuA, Moreno-MartetM, MechaM, et al.A Sativex®-like combination of phytocannabinoids as a disease-modifying therapy in a viral model of multiple sclerosis. Br J Pharmacol. 2015; 172:3579–3595.
12.
WatsonCW-M, PaolilloEW, MorganEE, et al.Cannabis exposure is associated with a lower likelihood of neurocognitive impairment in people living with HIV. J Acquir Immune Defic Syndr. 2020; 83:56–64.
13.
KapoorR, SharmaB, KanwarSS. Antiviral phytochemicals: an overview. Biochem Physiol Open Access. 2017; 6:1–7.
14.
SledzinskiP, ZeylandJ, SlomskiR, et al.The current state and future perspectives of cannabinoids in cancer biology. Cancer Med. 2018; 7:765–775.
15.
OrzalliMH, KaganJC. Apoptosis and necroptosis as host defense strategies to prevent viral infection. Trends Cell Biol. 2017; 27:800–809.
16.
LoweHIC, ToyangNJ, McLaughlinW. Potential of cannabidiol for the treatment of viral hepatitis. Pharmacognosy Res. 2017; 9:116–118.
17.
MaorY, YuJ, KuzontowskiPM, et al.Cannabidiol inhibits growth and induces programmed cell death in Kaposi sarcoma-associated herpesvirus-infected endothelium. Genes Cancer. 2012; 3:512–520.
18.
MechaM, FeliuA, InigoPM, et al.Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors. Neurobiol Dis. 2013; 59:141–150.
19.
LombardoS, CosentinoM. Internet use for searching information on medicines and disease: a community pharmacy-based survey among adult pharmacy customers. Interact J Med Res. 2016; 5:e22.
